Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration

CONCLUSIONS: Although contralateral retinal changes have been described for many other vascular endothelial growth factor inhibitors, there is little evidence for brolucizumab. We describe a repeated dose- and time-related effect on the uninjected eye in a case of nAMD.PMID:37424299 | DOI:10.1177/11206721231187429

Source: European Journal of Ophthalmology - July 10, 2023 Category: Opthalmology Authors: Paolo Mora Carlo Bellucci Lorenzo M Radice Francesca Manzotti Stefano Gandolfi Source Type: research